Carbapenemase-Producing *Acinetobacter baumannii* in China, Latin America and the Caribbean: A Systematic Review and Meta-Analysis

Haiyang Yu MD MPH, Guillermo Ezpeleta-Lobato MD MPH, Xu Han MD MPH, Yenisel Carmona-Cartaya MD MS, Dianelys Quiñones-Pérez MD MS PhD

**ABSTRACT**

**INTRODUCTION** Carbapenem-resistant *Acinetobacter baumannii* is a complex health problem, causing difficulties in clinical–therapeutic management worldwide. It is of particular concern in Latin America, the Caribbean and China, where it is an emerging health problem. Carbapenemases produced by these organisms inactivate carbapenem antibiotics. Monitoring circulating genotypes’ geographic dispersion contributes to more effective control measures. However, exhaustive studies on carbapenem-resistant *A. baumannii* are scarce.

**OBJECTIVES** Study the production of carbapenemases in clinical isolates of *A. baumannii* resistant to carbapenem antibiotics and the geographic distribution of the sequences circulating in China, Latin America and the Caribbean.

**DATA ACQUISITION** We followed PRISMA indications. We carried out a systematic search in Pubmed, BVS and CKNI on papers on *A. baumannii* and carbapenemases published during 2015–2020 in English, Spanish and Chinese, and selected 29 cross-sectional studies that met the search criteria. Studies were evaluated using JBI Critical Appraisal tools, and quantitative data were collated for meta-analysis using the Metaprop library in Stata15.

**DEVELOPMENT** OXA-type carbapenemases were detected in all studies; among *A. baumannii* resistant to carbapenem antibiotics, predominant types were OXA-23, OXA-24, OXA-54 and OXA-72; metallobetalactamases were identified less frequently than OXA carbapenemases. Only one clinical isolate producer of Class A carbapenemases (KPC) was identified in Colombia. In total, 41 sequence types were identified; in Latin America and the Caribbean the most common types were: ST79, ST25, ST1 and ST15; in China, the sequences ST195, ST208, ST191, ST368 and ST369 were the most prevalent. ST2 was found in both regions.

**CONCLUSIONS** The most prevalent carbapenemases and sequence types vary by region, indicating different ancestral strains. Microbiological surveillance, antibiotic use optimization, adequate infection treatment and timely control strategies are essential for carbapenem-resistant *A. baumannii* prevention and control in geographies such as Latin America, the Caribbean and China where such resistance is an emerging health problem.

**KEYWORDS** Acinetobacter baumannii, carbapenemase, genotype, epidemiology, Latin America, Caribbean region, China

**INTRODUCTION**

The genus *Acinetobacter* (*Acinobacter spp.*) is made up of several species. These gram-negative bacilli are among the most common nosocomial pathogens worldwide. *Acinetobacter baumannii* is the most clinically relevant species, due to its ability to develop various mechanisms that lend themselves to antibiotic resistance. [1] A member of the beta-lactam class (the same class of antibiotics as penicillins and cephalosporins), carbapenem antibiotics are the last resort in treating *A. baumannii* infections.

There has been a worldwide increase in carbapenem resistance observed in clinical isolates of *A. baumannii*. [2] The Latin American Antimicrobial Resistance Surveillance Network found *A. baumannii* to have high resistance to carbapenems in 15 countries in the region during 2014–2016. The percentage of resistant isolates varied from 8% to 89%. [3] In China in 2016, 71.4% of *A. baumannii* isolates were resistant to carbapenems. [4] WHO published a list of priority pathogens in 2017, including *A. baumannii*, *Pseudomonas aeruginosa*, and carbapenem-resistant *Enterobacteriaceae spp.* as critical priorities. [5]

The main mechanism of carbapenem resistance in *A. baumannii* (CRAB) strains is carbapenemases production. The most common of these are Ambler’s class D oxacillinases (OXAs). [2] Six subgroups of OXAs have been identified in *A. baumannii*: the species’ intrinsic carbapenemase OXA-51–like, and the acquired carbapenemases OXA-23–like, OXA-24–like, OXA-58–like, OXA-143–like, and OXA-235–like. [6] Class B metallobetalactamases (MBLs) are also a major threat because they are often located in mobile genetic elements, easily transferrable between bacteria. Four types of MBLs are frequently detected in *A. baumannii*: imipenemase (IMP), Verona imipenemase (VIM), Seoul imipenemase (SIM), and New Delhi betalactamase (NDM). [7]

Molecular characterization of *A. baumannii* isolates is very useful in identifying the source of an outbreak and in helping to control its spread. Multilocus sequence typing (MLST) is highly discriminative and has been applied successfully to several bacterial patho-

**IMPORTANCE**

This meta-analysis shows the different types of carbapenemases in *A. baumannii* in China, Latin America and the Caribbean, and the geographic distribution of the circulating sequence types. The data provide useful information for antibiotic resistance surveillance in the regions chosen for analysis, where this is an emerging health problem.
The emergence of carbapenem-resistant forms of \textit{A. baumannii} is a complex global problem, difficult to manage both clinically and therapeutically. Monitoring carbapenemase genotypes and molecular epidemiology studies contribute to more effective control measures. However, comparative analyses of circulating forms in different geographies are scarce. This work is a systematic review of published information on carbapenemase production and sequence types characterized in \textit{A. baumannii} isolates in China, Latin America and the Caribbean (LAC).

**DATA ACQUISITION**

We followed the SPIDER scheme in preparing this study.\cite{9} We carried out a systematic review of all relevant publications in 2015–2020, adjusted according to recommendations contained in PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).\cite{10}

**Search strategy and article selection** The search was carried out in the following databases: PubMed (Medline), BVS (Regional Portal, Virtual Health Library), and CNKI (Chinese database). We used the following keyword combinations: “carbapenem resistance” OR “carbapenemase producing” combined with “Acinetobacter baumannii” combined with the names of the following countries: “Argentina”, “Bahamas”, “Belize”, “Bolivia”, “Brazil”, “Chile”, “China”, “Columbia”, “Costa Rica”, “Cuba”, “Ecuador”, “Guatemala”, “Guyana”, “Haiti”, “Honduras”, “Jamaica”, “Mexico”, “Nicaragua”, “Panama”, “Paraguay”, “Peru”, “Salvador”, “Surinam”, “Trinidad”, “Uruguay”, and “Venezuela”. We selected articles in three stages: by title, by abstract content, and finally, according to information contained in the full text.

**Inclusion criteria** We included studies with the following characteristics: 1) observational studies with a cross-sectional design; 2) analysis of \textit{A. baumannii} clinical isolates in adult populations; 3) reports on CRAB; 4) detection of class A, B and D carbapenemases by molecular methods such as reverse-transcriptase polymerase chain reaction testing (RT-PCR) or MLST; 5) carbapenemase genotype analysis in LAC or China published in 2015–2020 in English, Spanish or Chinese.

**Exclusion criteria** Studies with one or more of the following characteristics were excluded: 1) contained no information on CRAB; 2) studied isolation in pediatric populations; 3) did not report on class A, B and D carbapenemase classes; 4) duplicated other research; and 5) studies that reported experiments in non-human subjects or were review articles, conference abstracts, meta-analyses or systemic reviews.

Review articles and meta-analyses were only considered in this review’s discussion section. Screening for inclusion was carried out individually by two team members. When there were differences of opinion, these were discussed with the principal investigator. Endnote X9 and Excel were used to manage references.

**Study quality evaluation** Study quality was evaluated by two researchers using the JBI Critical Appraisal Tools for Prevalence Studies.\cite{11} This tool includes nine items, each of which was scored as either ‘Yes’ (when the requirement was met), as ‘No’ (when the requirement was not met) or as ‘Not Clear’ (if it was unknown whether the requirement was met) or as ‘Not Applicable’.\cite{11} Studies were considered high quality when their score was ≥80% of the maximum possible score (6 or more items scored “Yes”), average quality when their score was 70%–79% (6–7 items scored ’Yes’), and low quality when their score was <70% (6 or fewer items scored ‘Yes’).

**Data extraction** Two team members carried out data selection and extraction individually, as well as bias risk analysis. We organized data on carbapenemase genotypes in China, Latin America and the Caribbean into a matrix (Table 1).

**Data analysis and statistics** We carried out a quantitative study (meta-analysis) on \textit{A. baumannii} carbapenemase genotypes and a qualitative study (qualitative descriptive synthesis) for sequence types, due to the great diversity of sequence types and differences between geographical areas. Two investigators undertook data analysis for the quantitative study. Statistical analysis was performed using the MetaProp module of Stata version 15 (StataCorp LLC U.S.A).\cite{12} and obtained estimates of the combined prevalence of predominant \textit{A. baumannii} carbapenemases in different regions, as well as their 95% confidence intervals (95% CI), which are represented in corresponding forest graphs (Figure 2).

We used either fixed-effect or random-effect models according to statistical heterogeneity between studies, which was assessed using the Cochran I2 statistic (a value of 0% indicates no heterogeneity; 25%, 50% and 75% are considered to have low, medium and high heterogeneity, respectively). Egger’s weighted linear regression test, combined with a funnel plot, was used to assess publication bias. An assessment of ‘no publication bias’ was made when the regression line started from the origin of the ordinate axis (Y) (publication bias increases as the line moves away from the Y coordinate’s origin). Statistical significance was assessed at 0.1 and not 0.05.\cite{13}

**DEVELOPMENT**

**Literature search, selection and validation** We initially selected 334 articles, which were reduced to 318 after eliminating duplicates. Of these, 261 were excluded for failure to meet inclusion criteria or because they were outside the scope of this review. Finally, we fully reviewed a total of 57 articles, and 29 were selected that met all established criteria, which were then included in the meta-analysis (Figure 1).

Medium-high scores were obtained upon evaluation of the cross-sectional observational studies (Table 2). In this study, 95% is...
used as expected prevalence in calculating sample size, as carbapenemase production is the CRAB’s dominant cause. Considering three studies on molecular isolate typing in hospitals,[14–16] the confidence level equal to 95% and precision equal to 5%, the estimated minimum CRAB sample size was 73. Consequently, we excluded 14 articles due to small sample size. Another 14 studies on carbapenemase genotyping were excluded for only reporting detection of Class D carbapenemases.

Carbapenemase characteristics Of the 29 studies included in this systematic review, 12 were from LAC, involving 11 countries and 17 were from 11 Chinese provinces. OXA-type carbapenemases were detected in all studies. In LAC, OXA-23, OXA-24, OXA-58 and OXA-72 genotypes were predominant, with respective prevalences of 0.73 (0.54–0.89), 0.06 (0.00–0.17), 0.03 (0.01–0.06) and 0.02 (0.00–0.06). In China, OXA-23, OXA-24 and OXA-72 were the most common, with respective prevalences of 0.91 (0.84–0.96), 0.03 (0.01–0.08), 0.02 (0.00–0.05). Metallobetaelactamases were less frequent than OXAs and were detected in only two countries in the Latin American and Caribbean region, with NDM 0.01 (0.00–0.01) as the predominant genotype, and in six Chinese provinces, with four predominant genotypes: NDM 0.02 (0.00–0.04), VIM 0.07 (0.00–0.21), IPM 0.02 (0.00–0.06) and SIM 0.01 (0.00–0.03) (Table 3). Only one clinical isolate Class A carbapenemase producer (KPC) was found, and it was isolated in Colombia.

According to the I2 values, high heterogeneity was observed among studies and we consequently used a random-effects model for the meta-analysis. Egger tests (p >0.1) and funnel plots show the characteristic shape of the asymmetric dispersion (Table 3 and Figure 2).

Molecular typing characteristics In 17 of the 29 studies, MLST was performed on CRAB isolates. In total, 41 sequence types (STs) were identified: 16 in LAC and 26 in China. Clear geographical differences were observed in predominant ST frequencies: ST79, ST25, ST1 and ST15 were more common in LAC; while ST195, ST208, ST191, ST368 and ST369 were found more frequently in China. ST2 was found in both (Table 2 and Figure 3).

**DISCUSSION**

Carbapenemase types Antibiotic overuse has led to an increase in multi-drug–resistant *Acinetobacter*. More than 50% of *Acinetobacter* spp. isolates in the United States, South America, India and China are resistant to carbapenem antibiotics.[46] This study verifies the high prevalence of OXAs in CRAB isolates in China, Latin America and the Caribbean. OXA-51–like carbapenemases (including OXA-51, 64, 65, 66, 68, 69, 70, 71, 78, 79, 80 and 82) occur naturally in *A. baumannii*. [47] OXA-24–like carbapenemases (including OXA-24, 25, 26, 40 and 72) have been found in both plasmid and chromosomal structures; OXA-58–like and OXA-23–like carbapenemases are encoded by plasmids,[48] which increases the probability of horizontal transmission. The plasmid-encoded carbapenemases OXA-23, OXA-24 and OXA-58 were the most frequently isolated carbapenemases in the two regions analyzed in this study. These results justify the non-inclusion of OXA-51 type carbapenemases, as their resistance to CRAB is intrinsic, and thus has little impact on amplifying carbapenem resistance in this species.

Carbapenemase OXA-72 was first identified in 2004 in an *A. baumannii* isolate from Thailand,[49] OXA-24–like carbapenemases (including OXA-24, 25, 26, 40 and 72) have been found in both plasmid and chromosomal structures; OXA-58–like and OXA-23–like carbapenemases are encoded by plasmids,[48] which increases the probability of horizontal transmission. The plasmid-encoded carbapenemases OXA-23, OXA-24 and OXA-58 were the most frequently isolated carbapenemases in the two regions analyzed in this study. These results justify the non-inclusion of OXA-51 type carbapenemases, as their resistance to CRAB is intrinsic, and thus has little impact on amplifying carbapenem resistance in this species.

Carbapenemase OXA-72 was first identified in 2004 in an *A. baumannii* isolate from Thailand,[49] and subsequently detected in Brazil, Mexico, Ecuador, Peru, China and Europe. [27,43,45,50,51] PXA-231 and OXA-253 were identified in Brazil and Peru, respectively. Both belong to the OXA-143–like group. OXA-231 and OXA-253 were reported the first time in *A. baumannii* isolates from Brazil (in 2007 and 2014, respectively) and still appear mainly in that country.[52,53] The dissemination of this subgroup requires monitoring, as it has been described more recently in Iran (2017), Colombia (2017) and Peru (2018). [45,54,55]
| Author, year, reference | Year isolated | Detection method | Place | Number of CRAB isolates | Carbapenem type (number detected) | Sequence type (n/N) | The study met all selection and quality criteria* | Adequate sample size | Data analysis with sufficient coverage of identified sample | Study quality |
|-------------------------|---------------|------------------|-------|------------------------|-----------------------------------|-------------------|-----------------------------------------------|-------------------|---------------------------------------------------|---------------|
| Chen F. (2018)[17]      | 2011          | PCR              | Hu Nan | 34                     | NA                                | IMP-5(22)         | OXA-23(33) OXA-24(29)                         | NA                | x                                                 | Medium        |
| Chen Y. (2018)[18]      | 2013–2017     | PCR              | Guang Dong | 66               | ND                                | NDM-1(3)          | OXA-23(60) OXA-24(19) OXA-58(3)               | NA                | x                                                 | High          |
| Chen Y. (2017)[19]      | 2011–2013     | PCR/MLST         | Shang Hai | 56               | NA                                | ND                | OXA-23(56)                                   | ST208(28/56) ST191(12/56) ST540(7/56) | No x x | Media |
| Han L. (2017)[20]       | 2013          | PCR              | Shan Xi  | 45               | ND                                | ND                | OXA-23(44)                                   | NA                | x                                                 | High          |
| Huang YZ. (2019) [21]   | 2016          | PCR/MLST         | Hu Nan  | 67               | NA                                | VIM(54)           | OXA-23(63) OXA-58(1)                         | ST195(28/67) ST368(9/67) ST829(8/67) ST210(2/67) ST90(2/67) ST136(2/67) | No x x | Medium |
| Jiang L. (2018)[22]     | 2017          | PCR/MLST         | Guang Dong | 122              | NA                                | VIM(7) SIM(2)     | OXA-23(115)                                  | ST195(10/28) ST208(9/28) ST1633(3/28) ST345(1/28) ST381(1/28) ST457(1/28) | No – x | High |
| Zhao L. (2018)[23]      | 2015–2016     | PCR              | An Hui   | 145              | ND                                | IMP-4(4)          | OXA-23(134) OXA-24(1)                        | NA                | Yes – – High |
| Song X. (2017)[24]      | 2013–2014     | PCR              | Shan Dong | 32               | ND                                | VIM(3)            | OXA-23(28)                                   | NA                | No x – High |
| Chen J. (2017)[25]      | 2015–2016     | PCR              | Jiang Xi | 64               | ND                                | VIM(56) NDM-1(17) SIM(12) | OXA-23(56) OXA-24(2) | ST368(102/248) ST195 (31/248) ST191 (29/248) ST369 (29/248) ST208 (21/248) ST381 (7/248) ST136 (2/248) ST229 (1/248) ST457 (1/248) | No x – | High |
| Huang G. (2016) [26]    | 2012–2014     | PCR/MLST         | Chong Qing | 248              | NA                                | NA                | OXA-23(163)                                  | Yes – – High |
| Chen Y. (2018)[27]      | 2014–2016     | PCR/MLST         | Liao Ning | 78               | NA                                | OXA-23(33) OXA-72(45) | ST2(9/78)                                    | No – x | High |
| Author, year, reference | Year isolated | Detection method | Place     | Number of CRAB isolates | Carbapenem type (number detected) | Sequence type (n/N) | The study met all selection and quality criteria* | The study did not meet these quality criteria: | Study quality |
|-------------------------|---------------|------------------|-----------|-------------------------|-----------------------------------|--------------------|-----------------------------------------------|-----------------------------------------------|-------------|
| Ning N. (2017)[29]      | 2009–2014     | PCR/MLST         | Bei Jing  | 101                     | NA NA                             | OXA-23(95) OXA-40(1) | ST191(32/101) ST195(31/101) ST208(15/101) ST368(6/101) ST469(6/101) ST218(2/101) ST373(2/101) ST383(2/101) ST429(2/101) ST369(1/101) | No – x High |            |
| Lu Q. (2019)[30]        | 2013–2015     | PCR              | Guang Xi  | 61                      | NA NDM-1(1)                        | OXA-23(44)          | ST1779(8/28) ST1789(6/28) ST195(5/28) ST191(2/28) ST368(2/28) ST369(2/28) ST208(21/55) ST369(14/55) ST195(11/55) ST451(6/55) ST381(1/55) | No x – High |            |
| Zhang Y. (2019)[31]     | 2017          | PCR/MLST         | An Hui    | 28                      | ND ND                             | OXA-23(25)          | ST1779(8/28) ST1789(6/28) ST195(5/28) ST191(2/28) ST368(2/28) ST369(2/28) ST208(21/55) ST369(14/55) ST195(11/55) ST451(6/55) ST381(1/55) | No x – High |            |
| Wu H. (2017)[32]        | 2015–2016     | PCR/MLST         | Shan Dong  | 55                      | NA ND                             | OXA-23(55)          | ST1779(8/28) ST1789(6/28) ST195(5/28) ST191(2/28) ST368(2/28) ST369(2/28) ST208(21/55) ST369(14/55) ST195(11/55) ST451(6/55) ST381(1/55) | No x x Medium |            |
| Li P. (2015)[33]        | Not mentioned | PCR              | Beijing   | 145                     | NA NA                             | OXA-23(134) OXA-58(1) | NA                                             | No – x High |            |
| Bado I. (2018)[34]      | 2010–2011     | PCR/MLST         | Uruguay   | 73                      | ND ND                             | OXA-23(58) OXA-58(2) | ST779(20/73) ST958(1/73)                         | Yes – – High |            |
| Camargo CH. (2016)[35]  | 2009–2013     | PCR/MLST         | Brazil    | 71                      | ND ND                             | OXA-23(68) OXA-72(2) | ST779(16/71) ST1(16/71) ST15(20/71)             | No x – High |            |
| Castillo SRA. (2017)[36]| 2010          | PCR              | Brazil    | 51                      | NA NA                             | OXA-23(31) OXA-58(2) | NA                                             | No x x Medium |            |
| Castillo Y. (2019) [37] | 2008–2013     | PCR              | Perú      | 46                      | ND ND                             | OXA-23(44) OXA-24(1) | NA                                             | No x – High |            |
| Gonzalez-Villoria AM. (2016)[38] | 2006–2013 | PCR/MLST         | México    | 192                     | NA ND                             | OXA-24(70) OXA-23(57) OXA-58(23) | ST758(9/22) ST417(2/22) | No – x High |            |
| Rodríguez CH (2017)[39] | 2016          | PCR/MLST         | Argentina | 100                     | ND ND                             | OXA-23(100)         | ST1(45/100) ST25(34/100) ST79(15/100)           | No – x High |            |
| Opaño-Capurro A. (2019)[40] | 1990–2015 | PCR/MLST         | Chile     | 56                      | NA ND                             | OXA-23(17) OXA-58(17) | ST162(4/56) ST15(3/56) ST109(2/56) ST318(1/56) | No x x Medium |            |
| Ovalle MV. (2017) [41]  | 2012–2014     | PCR              | Colombia  | 97                      | KPC(1) NDM(3) VIM(1)             | OXA-23(87) OXA-24(1) | No                                              | Yes – – High |            |
| Quiñones D. (2015) [42] | 2010–2012     | PCR              | Cuba      | 220                     | NDM (1)                           | OXA-23(139) OXA-24(35) OXA-58(6) | NA                                             | Yes – – High |            |
| Author, year, reference | Year isolated | Detection method | Place | Number of CRAB isolates | Carbapenem type (number detected) | Sequence type (n/N) | The study did not meet these quality criteria: Adequate sample size | Data analysis with sufficient coverage of identified sample | Study quality |
|------------------------|---------------|------------------|-------|------------------------|----------------------------------|---------------------|---------------------------------------------------------------|-----------------------------------------------------------|--------------|
| Brisolla LC (2019) [44] | 2008–2014     | PCR/MLST        | Brazil| 107                    | NA NA OXA-23(104) OXA-231(2) OXA-72(1) | ST730(43/107) ST317(28/107) ST1(10/107) ST79(8/107) ST107(2/107) ST986(1/107) ST175(1/107) ST22(1/107) | No | – x | High |
| Levy-Blitchtein S. (2018)[45] | 2014–2016 | PCR/MLST | Perú | 78 ND ND OXA-23(11) OXA-24(55) OXA-72(10) OXA-253(2) | ST2(7/16) ST79(6/16) ST1(2/16) ST3(2/16) ST108(1/16) | Yes | – – | High |

All were cross-sectional studies.

*Quality criteria: 1. The sample was appropriate to address the target population, 2. The sample was obtained using an adequate method, 3. The sample size was adequate 4. Participants and the context are described in detail 5. Data analysis was carried out with sufficient coverage of the identified sample 6. Effective methods were used to identify diseases or health problems 7. The sample was measured using standard and reliable methods for all participants 8. The statistical analysis was appropriate 9. Response rate was adequate or low response rate was adequately managed.

n: number of times the sequence was found; N: total isolates studied; NA: Not applicable (detection not performed); ND: Not detected; X: did not meet the requirement; ~: met the requirement.
Table 3: Meta-analysis of carbapenemase genotypes in China, Latin America and the Caribbean

| Place                                | Subgroups | Number of studies | n/N          | Prevalence (95% CI) | Heterogeneity, I² (%) | Heterogeneity p value | Egger’s test |
|--------------------------------------|-----------|-------------------|--------------|---------------------|-----------------------|-----------------------|--------------|
| Latin America and the Caribbean     | Class D   | OXA-23            | 11           | 804/1217            | 0.73 (0.54–0.89)      | 98.06                 | >0.001       | 0.42        |
|                                      |           | OXA-24            | 11           | 162/1217            | 0.06 (0.00–0.17)      | 96.96                 | >0.001       | 0.36        |
|                                      |           | OXA-58            | 11           | 49/1217             | 0.03 (0.01–0.06)      | 85.97                 | >0.001       | 0.87        |
|                                      |           | OXA-72            | 11           | 42/1217             | 0.02 (0.00–0.06)      | 88.20                 | >0.001       | 0.94        |
|                                      | MBLs      | NDM               | 9            | 4/933               | 0.01 (0.00–0.01)      | 0.00                  | >0.05        | 0.40        |
|                                      |           | VIM               | 9            | 1/933               | −                     | −                    |             |             |
|                                      |           | IMP               | 9            | 0/933               | −                     | −                    |             |             |
|                                      |           | SIM               | 9            | 0/933               | −                     | −                    |             |             |
| China                                | Class D   | OXA-23            | 17           | 1290/1499           | 0.91 (0.84–0.96)      | 94.42                 | >0.001       | 0.36        |
|                                      |           | OXA-24            | 17           | 51/1499             | 0.03 (0.01–0.08)      | 92.34                 | >0.001       | 0.11        |
|                                      |           | OXA-58            | 17           | 5/1499              | −                     | −                    |             |             |
|                                      |           | OXA-72            | 17           | 45/1499             | 0.02 (0.00–0.05)      | 91.07                 | >0.001       | 0.66        |
|                                      | MBLs      | NDM               | 14           | 21/1005             | 0.02 (0.00–0.04)      | 74.58                 | >0.001       | 0.57        |
|                                      |           | VIM               | 14           | 120/1005            | 0.07 (0.00–0.21)      | 97.36                 | >0.001       | 0.60        |
|                                      |           | IMP               | 14           | 26/1005             | 0.02 (0.00–0.06)      | 85.77                 | >0.001       | 0.21        |
|                                      |           | SIM               | 14           | 14/1005             | 0.01 (0.00–0.03)      | 57.92                 | >0.001       | 0.54        |

MBLs: Metallobetalactamases; n: Number of isolates with the genotype; N: Total number of carbapenem-resistant A. baumannii isolates
Number of studies: number of studies in which carbapenemases were identified

Figure 2: Forest plot and funnel plot for OXA-23 carbapenemase prevalence in China, Latin America and the Caribbean

A: OXA-23 carbapenemase prevalence in China
B: OXA-23 carbapenemase prevalence in Latin America and the Caribbean
The data obtained in this review show that MBLs have a very low prevalence and are mainly of the NDM, VIM and IPM types. Five Chinese provinces reported MBLs; Hu Nan and Jian Xi provinces, in particular, have very high prevalence of this type of carbapenemases. In LAC, only Cuba and Colombia detected MBLs, both of which had very low prevalence rates. A meta-analysis of Iranian isolates reported a prevalence of 21.9% and 6.2% of OXA-24 and OXA-58 carbapenemase isolates, respectively, and higher prevalences of MBLs (IMP, 16.7%; VIM, 12.3% and NDM, 2.7%)[56] than those found in LAC and China. A study in Egypt reported a prevalence of 95.7% IMP, 7.1% VIM and 42.9% GIM in A. baumannii isolates.[57] The emergence and spread of MBL-producing A. baumannii strains has been reported in the United States, Canada, Europe, Japan, Australia, Africa and the Middle East.[58] The differences in OXA and MBL prevalence between countries is likely due to pressures of antimicrobial selection, horizontal transfer of carbapenemase genes by mobile genetic elements (plasmids) between species, propagation of clones carrying these genes or to a combination of all these factors.

**Detected sequence types** MLST is considered the gold standard for detecting bacterial sequence types and is highly useful in epidemiology. This review includes 17 studies based on MLST. Due to the great diversity in sequence types and the differences between countries and provinces, we only carried out a descriptive qualitative study on these articles (Figure 3). In the case of LAC, these studies mainly originated in South America (namely in Brazil, Peru, Argentina, Colombia, Chile, Bolivia, Ecuador, Paraguay and Uruguay). The most common sequence types in the region were ST79, ST25, ST1 and ST15. ST79 had the widest geographic spread, and was detected in Ecuador, Peru, Brazil, Paraguay, Uruguay and Argentina,[34,35,39,43,45] which implies greater current dissemination than had been reported earlier (in a review carried out in 2018).[59] ST25 was detected in Bolivia, Paraguay, Uruguay and Argentina,[39,43] and had been previously identified in Honduras (2012) and Brazil (2013).[60,61] ST1 was found in isolates from Peru, Brazil and Argentina,[39,44,45] and was the predominant Argentinian isolate. ST15 was detected in Ecuador, Chile and Brazil; it was associated with carbapenemase production (mainly OXA-23-like carbapenemases), and has had rapid dissemination, mainly in South America.[62]

Eight provinces in China conducted multilocus sequence studies using MLST; ST195 and ST208 were the most common. These two sequence types have been found in other regions of the world and tend to become the dominant STs once introduced.[63–65] A study of the clinical and molecular characteristics of CRAB-produced bacteremia in China showed clones ST195 and ST208 to be predominant, and bacteremia resulting from A. baumannii clone ST195 was associated with higher lethality.[66] Clones ST191, ST368 and ST369 are moderately prevalent in China and are more commonly found in Asia than the rest of the world. Hospital infection by A. baumannii clones ST191 and ST369 has also been reported in China and South Korea.[67,68] The STs that are the most common in China are rarely reported in LAC; only ST369 has been reported in Mexico in 2020.[69] This may be the result of differing clonal ancestries in both regions and selection pressure from different antimicrobial use habits.

ST2 was found in both regions (Peru in LAC and Liao Ning in China). ST2 is prevalent in some countries in Pacific Asia and Europe,[70–74] but has not been reported with any frequency in LAC in the last five years. Although this study found ST2 to be associated with OXA-72, other studies have described ST2 A. baumannii clones as mainly being producers of OXA-23.[74–76] ST2’s dissemination in LAC merits consideration.

This study has provided estimates of the prevalence of different types of carbapenemases in A. baumannii in LAC and China, and the geographical distribution of different circulating CRAB STs and supports adjustments to resistance surveillance programming and antimicrobial management.

**Study limitations** There were some Latin American and Caribbean countries and Chinese provinces that produced no studies that met our selection criteria. Consequently, there is no information on carbapenemase-producing CRAB strain genotypes in these regions. Additionally, most studies do not detect Class A carbapenemases. This exclusion may have led to an overrepresentation of other carbapenemase classes and this preferential study of certain classes may have introduced bias. Finally, while the Egger test in not statistically significant and publication bias is unlikely, there is considerable heterogeneity between studies, as suggested by the asymmetric and sparse shape of the funnel plots. This could be due to insufficient sample size in the included studies, or to some variation (either geographical or temporal) in the strains or other methodological aspects such as differences in sample inclusion and exclusion criteria, among other factors.

**CONCLUSION**

A. baumannii resistance to carbapenem antibiotics is a global threat, and there is increasing diffusion of carbapenem-producing A. baumannii isolates and increasing geographic ST variation. Enzymes produced by regional isolates are generally very simi-
lar, while differences in STs are observed between China, Latin America and the Caribbean. Different regions have different epidemic CRAB strains, and it is important to consider local epidemiology in order to best tailor patient treatment. Studying circulating enzymes, clones and genetic lines facilitates understanding of region-specific resistance mechanisms.

Multidisciplinary collaboration is necessary (microbiologists, clinicians, epidemiologists and specialists in preventive medicine with experience in infection control), and will allow for early detection and study of resistance using molecular methods; adequate treatment, taking into consideration the patient’s clinical status, common circulating strains, and infection characteristics; and adoption of epidemiological measures aimed at multi-drug–resistant infection prevention and control, reducing transmission at community- and hospital-levels. A multidisciplinary approach can provide better results in managing a complex, multifactorial problem with major implications for public health.

REFERENCES

1. Wareth G, Brandt C, Sprague LD, Neubauer H, Pietz MW. Spatio-temporal distribution of Acinetobacter baumannii in Germany—a comprehensive systematic review of studies on resist ance development in humans (2000–2018). Microorganisms [Internet]. 2020 Mar 6 [cited 2021 Jun 25];(3):375. Available at: https://www.mdpi.com/2076-2607/8/3/375

2. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensive ly-resistant Acinetobacter baumannii infections. Drugs [Internet]. 2014 Aug 5 [cited 2021 Jun 25];(74):1215–33. Available at: https://doi.org/10.1007/s40265-014-0267-8

3. Pan American Health Organization [Internet]. Washington, D.C.: Pan American Health Organization; c2021. Documents. Magnitud y tendencias de la resistencia a los antimicrobianos en Latinoamérica. RELA/RA 2014, 2015, 2016. Informe resumido Organización Panamericana de Salud; 2020 Oct 16 [cited 2021 Jun 26]. Available at: https://www.paho.org/es/documents/magnitud-tendencias-resistencia-antimicrobianos-latinamerica-rela-2014-2015-2016. Spanish.

4. Hu F, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, al. [CHINET surveillance of bacterial resistance across China: report of the results in 2016]. Chin J Infect Chemother [Internet]. 2017 [cited 2021 Apr 13];(17)(5):481–91. Available at: http://wpmr.whocc.org.cn/admin/article/articleDetail?WPMPID=658380. Chinese.

5. World Health Organization [Internet]. Geneva: World Health Organization; c2021. Pedro. Press release. WHO publishes list of bacteria for which new antibiotics are urgently needed; 2017 Feb 27 [cited 2021 Jun 3]; [about 3 p.]. Available at: https://www.who.int/es/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.

6. Jeannot K, Diencourt L, Vaux S, Thouerez M, Ribeiro A, Coignard B, et al. Molecular epidemiology of carbapenem non-susceptible Acinetobacter baumannii in France, PLOS One [Internet]. 2014 Dec 17 [cited 2021 Jun 25];(9)(12):e115452. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115452

7. Ranjarb R, Zayeri S, Mirzaie A. Development of multiplex PCR for rapid detection of metallo-β-lactamase genes in clinical isolates of Acinetobacter baumannii. Iranian J Microbiol [Internet]. 2020 Apr [cited 2021 Jun 25];(12)(2):107–12. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244819/

8. Bantial SG, Seifert H, Hippler C, Domínguez Lazona MA, Wisplinghoff H, Rodríguez-Valera F. Development of a multiplex sequence typing scheme for characterization of clinical isolates of carbapenem-resistant Acinetobacter baumannii. J Clin Microbiol [Internet]. 2020 Dec 21 [cited 2021 Jun 30];49(3):4382–90. Available at: https://journals.asm.org/doi/abs/10.1128/JCM.43.9.4382-4390.2020

9. Cooke A, Smith D, Booth A. Beyond PICCO: The SPIDER tool for qualitative evidence synthesis. Qual Health Res [Internet]. 2012 Oct [cited 2021 Apr 13];(22)(10):1435–43. Available at: https://doi.org/10.1177/1049732312452938

10. Moher D, Liberati A, Tetzlaff J, Altman DG. Items of reference for public revision sistemáticas y metaanálisis: la Declaración PRISMA [Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement]. Rev Esp Nutr Hum Diet [Internet]. 2014 Sep 16 [cited 2020 Jun 6];18(3):172–81. Available at: https://doi.org/10.14036/ehndh.16.3.114. Spanish. English.

11. Munoz Z, Gómez A, Martin A, Dufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc [Internet]. 2015 Sep [cited 2020 Jul 25];(13)(3):147–53. Available at: https://journals.lww.com/ieebh/Full text/2015/09000/Methodological_guidance_for_systematic_reviews_of.6.aspx

12. Nyaga VN, Arbyn M, Aerts M. Metaprop: a stata command to perform meta-analysis of binomial data. Arch Public Health [Internet]. 2014 Nov 10 [cited 2020 Jul 7];72(39). Available at: https://doi.org/10.1186/2049-3258-72-39

13. Molina Arias M. Aspectos metodológicos del metaanálisis (1). Pediatr Atención Primaria [Internet]. 2018 Jul–Sep [cited 2020 Jul 20];79(207):297–302. Available at: http://sceilo.isciii.es/scielo.php?script=sci_arttext&pid =S1139-732020180000030. Spanish.

14. Hamidian M, Negro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microb Genom (Engl) [Internet]. 2019 May [cited 2021 May 13];5(10):e000306. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881685/

15. de Oliveira EA, de Paula GR, Mondino PJJ, Gomes Chagas TP, Bona de Mondino SS, Veirea de Mendonça-Souza CR. High rate of detection of OXA-23-producing Acinetobacter from two general hospitals in Brazil. Rev Soc Brasileira Med Trop [Internet]. 2019 Sep 5 [cited 2021 May 13];5(32):e20190243. Available at: https://doi.org/10.1590/0037-8682-2043-2019

16. Zhao L, Liu SY, Li JB, Ye Y. A multicenter study of hospital infection with carbapenem-resistant Acinetobacter baumannii. Chin J Infect Dis [Internet]. 2018 [cited 2020 Sep 30];20:36. Available at: http://rs.yiigle.com/CN311365201804/1050855.htm. Chinese.

17. Song X, Chen J, Zhai J, Zhu Y, Li C, Yang D. [A study on antibiotics resistance and carbapenemase genotype of Acinetobacter baumannii in intensive care unit of Qingdao]. Chin J Infect Dis [Internet]. 2017 [cited 2020 Sep 30];40(3):216–20. Available at: http://rs.yiigle.com/CN14454210703/978475.htm

18. Chen J, Xu X, Liu K, Hu X, Chen H, Chen K, al. [NDM-1 gene and other carbapenemase genes in Acinetobacter baumannii in Jiangxi area]. Chin J Infect Control [Internet]. 2017 [cited 2020 Aug 25];21(6). Available at: https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJF&filename=GRKZ201702003&link=MDPLAST2017. Chinese.

19. Huang ZY, Li J, Shui J, Wang HC, Hu YM, Zou XM. Co-existence of blaOXA-23 and blaVIM in carbapenem-resistant Acinetobacter baumannii isolates belonging to global complex 2 in a Chinese teaching hospital. Chinese Med J (Engl) [Internet]. 2019 May 20 [cited 2020 Aug 15];132(10):1166–72. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511418/

20. Chinese. Available at: http://rs.yiigle.com/CN311365201804/1050855.htm. Chinese.

21. Huang ZY, Li J, Shui J, Wang HC, Hu YM, Zou XM. Co-existence of blaOXA-23 and blaVIM in carbapenem-resistant Acinetobacter baumannii isolates belonging to global complex 2 in a Chinese teaching hospital. Chinese Med J (Engl) [Internet]. 2019 May 20 [cited 2020 Aug 15];132(10):1166–72. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511418/

22. Chinese. Available at: http://rs.yiigle.com/CN311365201804/1050855.htm. Chinese.

23. Chinese. Available at: http://rs.yiigle.com/CN311365201804/1050855.htm. Chinese.

24. Chinese. Available at: http://rs.yiigle.com/CN311365201804/1050855.htm. Chinese.

25. Chinese. Available at: http://rs.yiigle.com/CN311365201804/1050855.htm. Chinese.

26. Chinese. Available at: http://rs.yiigle.com/CN311365201804/1050855.htm. Chinese.

27. Chinese. Available at: http://rs.yiigle.com/CN311365201804/1050855.htm. Chinese.
Review Article

Chinese hospital: a cross sectional study. BMC Infect Dis [Internet]. 2018 Sep 29 [cited 2020 Aug 20];18:491. Available at: https://doi.org/10.1186/s12879-018-3359-3.

28. Jiang M, Liu L, Ma Y, Zhang Z, Li N, Zhang F, et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in a single institution over a 65-month period in north China. BMC Infect Dis [Internet]. 2017 Jan 5 [cited 2020 Sep 5];17:14. Available at: https://doi.org/10.1186/s12879-016-1101-1.

29. Lu Q, Wei B, L H, Zhang Y. [Drug resistance and genotyping of β-lactamase of Acinetobacter baumannii resistant to carbapenems in western GuanQiu]. Lab Med Clin [Internet]. 2019 [cited 2020 Aug 20];20(16):12. Available at: https://www.ncbi.nlm.nih.gov/kcsms/detail/detail.aspx?dbcode=CJFD&dbname=CJFQ201902&v=%25mmd2BHO2kkKxIJBrljb3MTYg3m9hhkcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFQ20192&v=%25mmd2BHO2kkKxIJBrljb3MTYg3m9hh.

30. Li P, Niu W, L I, Lei H, Liu W, Zhao X, et al. Rapid detection of Acinetobacter baumannii and molecular characterization of carbapenem-resistant A. baumannii in two comprehensive hospitals of Beijing, China. Front Microbiol [Internet]. 2015 Sep 23 [cited 2020 Sep 24];5. Available at: https://www.frontiersin.org/articles/10.3389/fmicb.2015.00167/full.

31. Bado I, Papa-Ezdra AF, Delgado-Bias JF, Gauto D, M, Gutierrez C, Cordeiro NF, et al. Molecular characterization of carbapenem-resistant Acinetobacter baumannii in the intensive care unit of Uruguay’s University Hospital identifies the first rmC gene in the species. Microb Drug Resist [Internet]. 2018 Sep 1 [cited 2020 Aug 20];24(7):1012–9. Available at: http://dx.doi.org/10.1089/mdr.2017.0300.

32. Camargo CH, Ribeiro Tiba M, Saes MR, de Vasconcellos FM, dos Santos LF, Caló Romero E, et al. Emergence and persistence of high-risk clones among MDR and XDR A. baumannii at a Brazilian teaching hospital. Front Microbiol [Internet]. 2019 Jan [cited 2020 Sep 20];9:2989. Available at: https://www.frontiersin.org/articles/10.3389/fmicb.2018.02989.

33. Levy-Bltchtein S, Roca I, Plasencia-Rebata S, Vicente-Taboada W, Velásquez-Pomar J, Muñoz L, et al. Emergence and spread of carbapenem-resistant Acinetobacter baumannii international clone II and other carbapenemases. J Antimicrob Chemother [Internet]. 2017 Apr 4 [cited 2020 Sep 5];71:119. Available at: https://doi.org/10.1093/jac/sdy142/sdy1102-11-27.

34. Kim U, Joo CH, Cho SK, Park H-K, Jang H-C. Update on the epidemiology, treatment, and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam Med J [Internet]. 2014 Aug 20 [cited 2020 Oct 20];50(2):37–44. Available at: https://doi.org/10.4058/cmj.2014.50.2.37.

35. Castillo Y, Nieto C, Autocondo L, Jacob J, García C. Bacteriemia por Acinetobacter baumannii productor de oxacilinas en hospitales de Lima, Perú. Rev Perú Med Exp Salud Publica [Internet]. 2019 [cited 2020 Aug 15];36(2):364–6. Available at: http://europepmc.org/abstract/MED/27547405.

36. Li P, Niu W, L I, Lei H, Liu W, Zhao X, et al. Molecular epidemiology of multi-drug resistant Acinetobacter baumannii circulating in Chilean hospitals. Infect Genet Evol [Internet]. 2019 [cited 2020 Sep 7];93:93–7. Available at: http://dx.doi.org/10.1016/j.meegid.2019.04.002.

37. Quinones D, Carvajal I, Pérez H, Martín M, García S, et al. High prevalence of bla OXA-23 in Acinetobacter spp and detection of bla NDM-1 in A. soli in Cuba: report from National Surveillance of Resistance to Antibiotics (NSRA). J Antimicrob Chemother [Internet]. 2012;67 Suppl 1:S1567134819301091.

38. Rodríguez-Costa F, Cayó R, Pereira Matos A, Girandello R, Martins WMBS, Carrara-Marron FE, et al. Temporal evolution of carbapenem-resistant Acinetobacter baumannii. Emergence of bla OXA-143 into bla OXA-231 coupled with mobilization of ISAba1 upstream occA1. Res Microbiol [Internet]. 2019 Jan-Feb [cited 2021 Jun 27];170(1):53–9; Available at: https://www.journals.elsevier.com/resmicrobiol/.

39. Costache M, Cristea VC, et al. First report of OXA-143-lactamase producing Acinetobacter baumannii in Qom, Iran. Iranian J Basic Med Sci [Internet]. 2017 Nov [cited 2021 Jun 29];20(11):1262–6. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749364/.

40. Saavedra SY, Prada-Cardozo D, Verónica R, Pérez-Carodina H, Hidalgo AM, Nilse González M, et al. Whole-genome sequence of a Colombi-an Acinetobacter baumannii strain, a coproducer of OXA-72 and OXA-255-like carbapenemases. Genome Announce [Internet]. 2017 Feb 16 [cited 2021 Jun 26];5(7):e01558-16. Available at: https://doi.org/10.1101/gsm.01558-16.

41. Beigverdi R, Sattari-Maraji A, Emaneini M, Jabal-Mali M, Georgescu M, Gheorghe I, Dudu A, Czobor I, Costache M, Cristea VC, et al. First report of OXA-72 producing Acinetobacter baumannii in Romania. New Microb New Infect [Internet]. 2016 Jul [cited 2021 Jun 27];10:1–4. Available at: http://www.sciencedirect.com/science/article/pii/S0295621X16000560.

42. Rodríguez-Bañuelos RH, Busto Z, Rivas J, Santibáñez E, et al. Molecular characterization of carbapenem-resistant Acinetobacter baumannii from intensive care units in Goldenha, Brazil: molecular and drug susceptibility pro-patterns. PLoS One [Internet]. 2017 [cited 2020 Aug 13];12(5):e0176790. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419545/.

43. Rodríguez Buenahora RD, Busto Zarahet DE, Caicedo Sánchez DC, Cadena Sarmiento DC, Castellanos Gómez C, Acinetobacter baumannii: patógeno multirresistente emergente. MEDIS U [Internet]. 2016 [cited 2020 Oct 20];47(11):369–73. Available at: http://dx.doi.org/10.1016/j.medis.2016.09.006.

44. Salas J, Aguilera AF, Barcelo MA, Zanchi Z, Mazziotti R. First report of OXA-143-lactamase producing Acinetobacter baumannii in Qom, Iran. J Infect Genet [Internet]. 2019 [cited 2021 Jun 27];12(6):576–7. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64913019101.

45. Almamawy NM, Hammad Zaki M. Molecular study of Acinetobacter baumannii isolates for metallic-ß-lactamases and extended-spectrum-ß-lactamases genes in intensive care unit, Mansoura University Hospital, Egypt. Int J Microbiol [Internet]. 2017 [cited 2021 Apr 10];2017:300530.
stream infections caused by Acinetobacter baumannii: a case−control study. Diagnostic microbiology and infectious disease. Diagn Microbiol Infect Dis [Internet]. 2021 Feb [cited 2021 Jun 29];99(2):115229. Available at: https://www.sciencedirect.com/science/article/pii/S0732889320306064

Jun SH, Lee DE, Hwang HR, Kim N, Kim HJ, Lee YC, et al. Clonal change of carbapenem-resistant Acinetobacter baumannii isolates in a Korean hospital. Infect Genet Evol [Internet]. 2021 Sep [cited 2021 Jun 29];93:104935. Available at: https://www.sciencedirect.com/science/article/pii/S156713482100232X

Meijje J, Li L, Liu S, Zhang Z, Li N, Zhao S. Extensively drug resistant Acinetobacter baumannii ST369 infection in emergency intensive care unit in Shandong Province, China. Res Square [Internet]. 2020 Jan 31 [cited 2020 Nov 10]. Available at: http://europepmc.org/abstract/ PPR/PPR126539

López-Durán PA, Fonseca-Coronado S, Lozano-Trenado LM, Araujo-Betanzos S, Rugero-Trujillo DA, Vaughan G, et al. Nosocomial transmission of Extensively drug resistant Acinetobacter baumannii strains in a tertiary level hospital. PLoS One [Internet]. 2020 Apr 17 [cited 2020 Nov 10];15(4):e0231829. Available at: https://doi.org/10.1371/journal.pone.0231829

Khursid M, Shafi M, Ashfaq UA, Aslam B, Wasseem M, Xu Q, et al. Dissemination of blaOXA-23-harboursing carbapenem-resistant Acinetobacter baumannii clones in Pakistan. J Glob Antimicrob Resist [Internet]. 2020 Jun [cited 2021 Jun 30];21:357–62. Available at: https://www.sciencedirect.com/science/article/pii/S2217652020300023

Khantayaporn P, Kanathum P, Chomnawang MT. Predominance of international clone 2 multidrug-resistant Acinetobacter baumannii clinical isolates in Thailand: a nationwide study. Ann Clin Microbiol Antimicrob [Internet]. 2021 Mar 20 [cited 2021 Jun 30];20(19). Available at: https://doi.org/10.1186/s12941-021-00424-z

Shirazi AS, Shafei M, Solgi H, Aslani MM, Azizi O, Badamasti F. Different virulence capabilities and ompA expressions in ST2 and ST513 of multidrug-resistant Acinetobacter baumannii. Curr Microbiol [Internet]. 2019 Jun [cited 2021 Jun 30];79(6):723–31. Available at: https://doi.org/10.1007/s00284-019-01686-9

Matsui M, Suzuki M, Suzuki M, Yatsuyanagi M, Hutin MT. Predominance of international clone II lineage in Japan. Antimicrob Agents Chemother [Internet]. 2018 Jan 25 [cited 2021 Jun 30];62(2):e02190-17. Available at: https://journals.asm.org/doi/10.1128/AAC.02190-17

Kostyaner T, Xavier BB, García-Castillo M, Lam-mens C, Bravo-Ferrer Acosta J, Rodríguez-Baño J, et al. Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study. Int J Antimicrob Agents [Internet]. 2021 Jun [cited 2021 Jun 30];57(6):106345. Aval-

https://doi.org/10.37757/MR2022.V24.N1.8

THE AUTHORS
Haiyang Yu, physician specializing in preventive medicine and public health with a master’s degree in public health. Nosocomial Infection Management Department, Chongqing University Three Gorges Hospital, Chongqing, China. E-mail: dia@ipk.sld.cu, physician specializing in microbiology with a master’s degree in public health. Head of the International Travelers’ Health Department, Bizkaia International Vaccination Center, Bilbao, Spain. E-mail: orcid.org/0000-0003-0970-6352

Guillermo Ezepeleta-Lobato, physician with dual specialties in microbiology & parasitology and preventive medicine & public health, with a master’s degree in public health. Head of the International Travelers’ Health Department, Bizkaia International Vaccination Center, Bilbao, Spain. E-mail: orcid.org/0000-0003-2343-1818

Yenisel Carmona-Cartaya, physician specializing in microbiology with a master’s degree in bacteriology and mycology. Healthcare-Associated Infections National Laboratory, IPK, Havana, Cuba. E-mail: orcid.org/0000-0003-1241-5302

Dianelys Quinones-Pérez (corresponding author: dia@ipk.sld.cu), physician specializing in microbiology, with a master’s degree in bacteriology and mycology, and a doctorate in medical sciences. Healthcare-Associated Infections National Laboratory, IPK, Havana, Cuba. E-mail: orcid.org/0000-0003-4506-6890

 disclosures: None

Submitted: February 2, 2021
Approved for publication: November 16, 2021
Disclosures: None

Review Article